Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erick Gamelin

Showing results (11-20 of 47) with videos related to

Pageof 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patientsElisabeth Rouits, Michèle Boisdron-Celle, Agnès Dumont, et al.
Clinical Colorectal Cancer|June 12, 2012
Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept studyOlivier Capitain, Andreaa Asevoaia, Michele Boisdron-Celle, et al.
Cancer Letters|January 3, 2006
Tumor quantification of several fluoropyrimidines resistance gene expression with a unique quantitative RT-PCR method. Implications for pretherapeutic determination of tumor resistance phenotypeMaud Barbado, Laurence Preisser, Michele Boisdron-Celle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancerLaurence Gamelin, Michele Boisdron-Celle, Remy Delva, et al.
Molecular Cancer Therapeutics|November 24, 2006
Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil toleranceAlain Morel, Michele Boisdron-Celle, Luc Fey, et al.
Molecular Cancer|July 8, 2011
Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cellsAgnes Basseville, Laurence Preisser, Sophie de Carné Trécesson, et al.
The Journal of Biological Chemistry|June 3, 2010
The cdk5 kinase regulates the STAT3 transcription factor to prevent DNA damage upon topoisomerase I inhibitionSandy Courapied, Hélène Sellier, Sophie de Carné Trécesson, et al.
International Journal of Cancer|April 21, 2009
Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophagesDorothée Duluc, Murielle Corvaisier, Simon Blanchard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2007
Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathwayLaurence Gamelin, Olivier Capitain, Alain Morel, et al.
Molecular Cancer|August 5, 2010
Regulation of the Aurora-A gene following topoisomerase I inhibition: implication of the Myc transcription factorSandy Courapied, Julia Cherier, Arnaud Vigneron, et al.
Pageof 5

Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patientsElisabeth Rouits, Michèle Boisdron-Celle, Agnès Dumont, et al.
Clinical Colorectal Cancer|June 12, 2012
Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept studyOlivier Capitain, Andreaa Asevoaia, Michele Boisdron-Celle, et al.
Cancer Letters|January 3, 2006
Tumor quantification of several fluoropyrimidines resistance gene expression with a unique quantitative RT-PCR method. Implications for pretherapeutic determination of tumor resistance phenotypeMaud Barbado, Laurence Preisser, Michele Boisdron-Celle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancerLaurence Gamelin, Michele Boisdron-Celle, Remy Delva, et al.
Molecular Cancer Therapeutics|November 24, 2006
Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil toleranceAlain Morel, Michele Boisdron-Celle, Luc Fey, et al.
Molecular Cancer|July 8, 2011
Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cellsAgnes Basseville, Laurence Preisser, Sophie de Carné Trécesson, et al.
The Journal of Biological Chemistry|June 3, 2010
The cdk5 kinase regulates the STAT3 transcription factor to prevent DNA damage upon topoisomerase I inhibitionSandy Courapied, Hélène Sellier, Sophie de Carné Trécesson, et al.
International Journal of Cancer|April 21, 2009
Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophagesDorothée Duluc, Murielle Corvaisier, Simon Blanchard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2007
Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathwayLaurence Gamelin, Olivier Capitain, Alain Morel, et al.
Molecular Cancer|August 5, 2010
Regulation of the Aurora-A gene following topoisomerase I inhibition: implication of the Myc transcription factorSandy Courapied, Julia Cherier, Arnaud Vigneron, et al.
Pageof 5